Featured News
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Innovator-of-Year to AMPEL
COMPANY
Virginia Catalyst Announces AMPEL as Grant Round 14 Awardee
The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2 million in grants to four life and bioscience projects in the Commonwealth of Virginia, pending execution of the grant agreements.
Central Virginia is fertile ground for innovations in biotech and life sciences
“We could have formed this company anywhere, but we chose Charlottesville because of the great community that’s here,” says Dr. Amrie Grammer, co-founder, president and chief scientific officer of AMPEL BioSolutions.
In Conversation: Dr. Amrie Grammer, Co-founder, President and Chief Scientific Officer, AMPEL Biosolutions
These are exciting times for the AMPEL team. BioBuzz thought it was a great time to catch up with AMPEL’s Co-founder, President, and Chief Scientific Officer Dr. Amrie Grammer to discuss her founder’s journey and AMPEL’s promising future.
First Lady of Virginia visits AMPEL
Suzanne Youngkin shared the goals of the W+g initiative focused on wellbeing and workforce in Virginia during her March 30th visit to AMPEL BioSolutions, a women-owned business founded, headquartered and growing in Charlottesville. The focus of AMPEL's business is...
Virginia Catalyst Awards $2 Million in Grants to Support Life Sciences in the Commonwealth
The critical mass achieved by these collaborations provides Virginia with competitive advantages over other states and has resulted in significant outside capital being invested to finance the commercialization of Virginia’s innovations and create significant high-paying jobs for the Commonwealth.
Charlottesville-area company receives praise for internship program
AMPEL BioSolutions, LLC. is being recognized by Virginia officials for its internship program. It is the only tech company in Charlottesville recognized this cycle. AMPEL says its priority is contributing to knowledge of the future. Interns are able to examine RNA, work on projects, and provide design support for doctors
PLATFORM
Bloomberg’s “The Tape” Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
Health + Tech – Future of Precision Medicine With Dr. Amrie Grammer
CLICK FOR ORIGINAL ARTICLE >
Dr. Amrie Grammer, co-founder, president and chief scientific officer of AMPEL BioSolutions, joins hosts Holly Buckley and Kristen McDermott Woodrum on this episode of Health+Tech.
AMPEL BioSolutions Announces Gene-Based Lupus Diagnostic At Biotech Showcase In San Francisco
AMPEL BioSolutions’ Co-Founder and COO/CSO Dr. Amrie Grammer today at the Biotech Showcase at JP Morgan Healthcare announces the kickoff of a Series A $12.5M raise to commercialize LuGENETM, a gene-based diagnostic.
MI/AL for Diagnosis & Prognosis
Presentation by Amrie Grammer, Ph.D, COO/CSO, AMPEL BioSolutions at the Precision Medicine World Conference on June 28, 2022
AMPEL BioSolutions focused on developing clinical blood test predicts the correct drug for a patient
AMPEL BioSolutions’ Co-Founder and COO/CSO Dr. Amrie Grammer today at the Biotech Showcase at JP Morgan Healthcare announces the kickoff of a Series A $12.5M raise to commercialize LuGENETM, a gene-based diagnostic.
PRODUCTS
AMPEL BioSolutions Selected as Member of Prestigious Federal Health Innovation ARPA-H Network
AMPEL BioSolutions has been selected as a member – or “spoke” – of the Customer Experience Hub of ARPANET-H, a prestigious nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
Today AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
On behalf of LuCIN investigators, I am pleased to report the results of Krill Oil supplementation for Lupus which found that patients are, indeed, deficient in omega3 and this can be safely corrected
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
Today AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients.
A new tool in the fight against autoimmune disease lupus
There is a new way to detect lupus before it causes more significant damage. LuGENE, a new blood test by AMPEL BioSolutions, helps forecast flare-ups and recognizes targets for effective drug options based on genomic data it reveals.
AMPEL BioSolutions Building Evidence for Prognostic Potential of Lupus Molecular Subtyping Test
AMPEL BioSolutions is recruiting individuals with systemic lupus erythematosus (SLE) into an observational study of its blood-based prognostic gene expression assay LuGene to demonstrate a correlation between test results and standard clinical evaluations.
PARTNERS
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
Research has shown that people with lupus are at an elevated risk of inflammation and cardiovascular complications,” said Dr. Amrie Grammer, AMPEL BioSolutions’ Co-Founder, President and CSO
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
On behalf of LuCIN investigators, I am pleased to report the results of Krill Oil supplementation for Lupus which found that patients are, indeed, deficient in omega3 and this can be safely corrected
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
The ORKIDS clinical trial of Krill Oil supplementation for Lupus was a team effort that documented patients were uniformly omega-3 fatty acid deficient which was reversible with Krill Oil supplementation.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
The results indicate that Lupus patients have suboptimal omega-3 (measured in red blood cell membranes using the standard omega3 index) which was normalized by one month supplementation with Krill Oil.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
AMPEL works with Pharma/Biotech customers as a CRO designing & operationalizing clinical trials as well as a biomarker partner for target identification, pre-clinical models, post-hoc analysis and real-time enrichment during clinical trial enrollment.
Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity
CLICK FOR ORIGINAL ARTICLE > CHARLOTTESVILLE, Va., July 15, 2024 /PRNewswire/ -- Today AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease...